Medicare's decision to deny coverage for the first new Alzheimer's treatment the FDA has approved in nearly 20 years will ...
Cambridge-based Spirea, created to advance a new generation of antibody drug conjugate (ADC) therapeutics, has secured funding of £2.4 million with investments from high-profile UK and US ...